Secondly, we have demonstrated in our program consistent metabolic benefits that now a diabetes agent can't just control blood sugar, it has to control other things as well; body weight, blood pressure ideally and this translating then to long-term benefits and cardiovascular risks and these of course are the trials that are required in Phase 3. So that's part of our core strategy here.

Read the rest of this transcript for free on seekingalpha.com

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

4 Smaller Biotech Names Worth Researching

7 Things to Watch in Biotech Now

These 3 Biotech Stocks Are Already Moving Wildly on Thursday